

Afatinib for treating advanced squamous non- small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)

Technology appraisal guidance

Published: 24 May 2017

www.nice.org.uk/guidance/ta444

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy. This is because Boehringer Ingelheim did not provide an evidence submission.

Information

If NHS organisations wish to consider afatinib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-2510-0